Qurient partners with Lonza's Synaffix to introduce next-generation dual-payload 카지노 바카라 technology

[by Yu, Suin] Qurient announced on September 25 that it has entered into a licensing agreement with Synaffix B.V., a clinical-stage antibody-drug conjugate (카지노 바카라) platform company and subsidiary of Switzerland-based Lonza, to advance the development of dual-payload 카지노 바카라s.

The agreement is structured as a platform technology license for the development of dual-payload 카지노 바카라s. Under its terms, Qurient has secured a non-exclusive license to leverage Synaffix's proprietary 카지노 바카라 platform technology for its dual-payload 카지노 바카라 development. The deal is valued at USD 249.5 million (approximately KRW 349.5 billion), including an upfront payment as well as payments tied to development progress, regulatory approvals in the U.S. and Europe, and future sales-based milestone payments.

Dual-payload 카지노 바카라s are engineered to simultaneously deliver two payloads with distinct mechanisms of action to target cancer cells, a design intended to boost therapeutic efficacy while reducing the risk of resistance to a single payload. According to the companies, this approach also offers the potential to broaden the therapeutic window, particularly for patients with refractory cancers, while minimizing toxicity to healthy tissues.

The collaboration aims to tackle unmet medical needs in solid tumors through the development of a dual-payload 카지노 바카라 combining Qurient's CDK7 inhibitor and Synaffix's exatecan-based technology. Under the agreement, Qurient will gain access to Synaffix's site-specific 카지노 바카라 platform technologies, including GlycoConnect, the HydraSpace polar spacer, and exatecan-based linker-payload technology. In addition, Qurient will benefit from the support of parent company Lonza, which brings industry-leading expertise in the development and manufacturing of bioconjugates.

Under the agreement, Lonza will oversee the production of components tied to Synaffix's proprietary technologies, while Qurient will take charge of the research, development, manufacturing, and commercialization of the 카지노 바카라, including the production of its proprietary CDK7 inhibitor.

"Dual-payload 카지노 바카라s represent a new frontier in targeted antibody therapeutics. We are eager to advance this novel combination of our CDK7 inhibitor and Synaffix's SYNtecan linker-payload toward successful development," said Nam Ki-yean, CEO of Qurient.

"The synergy between Qurient's proprietary technology and Synaffix's industry-leading platform holds strong potential for application across a broader spectrum of targets and antibodies. We intend to continue exploring these opportunities," Nam further commented.

"This agreement with Qurient serves as a strong testament to the versatility of our industry-leading 카지노 바카라 platform technology. The development of dual-payload 카지노 바카라s utilizing our technology further demonstrates our ongoing commitment to pioneering innovation in the 카지노 바카라 sector," stated Peter van de Sande, CEO of Synaffix.

Meanwhile, Lonza, one of the world's largest contract development and manufacturing organizations (CDMOs), with more than 19,000 employees on five continents, partners with pharmaceutical and biotechnology companies to bring innovative technologies to market and transform them into therapeutic solutions. By integrating cutting-edge science, advanced technologies, and efficient production systems, Lonza enables its clients to deliver life-saving and quality-enhancing treatments to patients worldwide. In H1 2020, the company reported revenues of CHF 3.6 billion (approximately USD 4.4 billion) and an adjusted EBITDA of CHF 1.1 billion.

Synaffix is ​​a biotechnology company specializing in the development of 카지노 바카라 candidates through its clinical-stage 카지노 바카라 platform technologies. Its 카지노 바카라 platform is built on three core technologies, GlycoConnect, HydraSpace, and toxSYN, which enable antibody developers to create best-in-class 카지노 바카라s under a single technology license agreement. Supported by a secure supply chain, these platforms also help shorten timelines to clinical entry. Synaffix, which commercializes its patented technologies through licensing, was acquired by Lonza in June 2023.